Cardinal Health: I'm Still Buying After Checking The Numbers

Cardinal Health delivered FY2026 revenue growth of 14%, gross-margin expansion of 20%, and roughly doubled free cash flow, supporting a continued Buy view. FY2027 guidance calls for 13%-15% non-GAAP EPS growth, driven by improving profitability in Pharmaceutical and Specialty Solutions and higher-margin Other segments. Thin margins and elevated current liabilities remain balance-sheet and execution risks.

Analysis

The investable question is whether CAH can convert earnings growth into a durable rerating rather than remain valued as a low-margin distributor. Incremental profit from Specialty and non-distribution businesses should carry materially higher contribution margins than core drug distribution, making mix—not top-line growth—the key driver of FY2027 multiple expansion. If that mix shift is validated, CAH has room to close part of its historical valuation discount to Cencora (COR) and McKesson (MCK).

Cash flow quality is the principal near-term diligence item. A working-capital-driven cash-flow step-up can reverse quickly if inventory, customer receivables, or supplier-payment terms normalize; investors should focus on operating cash flow conversion versus non-GAAP EPS over the next two quarterly prints, not the annual free-cash-flow headline. A miss on conversion would likely cap the rerating even if EPS remains within guidance, because distributors are valued on confidence in recurring cash generation.

Over 1-3 months, the catalyst path is upward earnings-estimate revisions and evidence that Specialty profitability is scaling without requiring disproportionate investment. Over 6-18 months, the upside case depends on higher-margin assets becoming large enough to reduce sensitivity to pharmaceutical pricing pressure and customer concentration. The contrarian risk is that consensus treats the guidance range as de-risked: reimbursement pressure, generic-price deflation, or a reversal in working-capital timing could expose how little absolute margin cushion exists in the core distribution model.

Key Decisions for Investors

• Initiate a 3-6 month long CAH / short MCK pair in equal dollar beta-adjusted sizing if CAH continues to trade at a material forward-EPS multiple discount. Thesis: CAH’s mix-driven margin expansion can narrow the valuation gap; exit if CAH’s next reported operating-cash-flow conversion falls below guidance-consistent levels or Specialty profit growth decelerates.
• For outright exposure, accumulate CAH ahead of the next earnings release rather than chase a post-guidance move; target a 10-15% upside from estimate revisions and partial multiple convergence, with a 7-8% risk limit tied to a guidance reduction or evidence of working-capital unwind.
• Monitor COR and MCK for relative read-throughs on pharmaceutical distribution economics. Broadly improving distributor margins favors a sector basket; CAH-specific deterioration versus peers would falsify the company-specific mix thesis and argues for rotating exposure into COR.
• Do not add leverage through calls until management discloses enough detail to separate recurring free-cash-flow improvement from payment-term effects. Treat a sequential rise in receivables or inventory materially faster than operating profit as an alert to reduce CAH exposure.